Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences Inc. closed $7.02 below its 52-week high ($98.90), which the company achieved on November 11th.

GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...

Mount Gilead traveled to Cardington for a rivalry girls basketball game in the Knox Morrow Athletic Conference on Friday ...

Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.

BofA Securities has recently resumed Gilead Sciences Inc (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.37 which represents a slight increase of $0.36 or 0.39% from the prior close of $92.01. The stock opened at $92.59 and ...